Drug Profile
Research programme: Janus kinase 2 inhibitors - SuperGen
Alternative Names: SGI-1252Latest Information Update: 26 Sep 2011
Price :
$50
*
At a glance
- Originator SuperGen
- Developer Astex Pharmaceuticals
- Class Small molecules
- Mechanism of Action Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 19 Nov 2009 Preclinical pharmacodynamics data presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
- 11 Dec 2007 Pharmacodynamics data from a preclinical study in cancer presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH-2007)
- 01 Aug 2007 Preclinical trials in Cancer in USA (PO)